abs423.txt	purpose		the	incidence	of	localized	prostate	cancer	has	decreased	with	shifts	inprostate	cancer	screening		while	recent	population	based	studies	demonstrated	astable	incidence	of	locoregional	prostate	cancer		they	categorized	organconfined		extraprostatic	and	lymph	node	positive	disease	together		however		toour	knowledge	the	contemporary	incidence	of	prostate	cancer	with	pelvic	lymphnode	metastases	remains	unknown	materials	and	methods		we	used	seer	(surveillance		epidemiology	and	end	results)data	from	2004	to	2014	to	identify	men	diagnosed	with	prostate	cancer		weanalyzed	trends	in	the	age	standardized	prostate	cancer	incidence	by	stage		theimpact	of	disease	extent	on	mortality	was	assessed	by	adjusted	cox	proportionalhazard	analysis	results		during	the	study	period	the	annual	incidence	of	nonmetastatic	prostatecancer	decreased	from	5	119	1	to	2	931	9	per	million	men	(ir	0	57		95%	ci0	56-0	58		p	<0	01)	while	the	incidence	of	pelvic	lymph	node	metastases	increasedfrom	54	1	to	79	5	per	million	men	(ir	1	47		95%	ci	1	33-1	62		p	<0	01)		theincidence	of	distant	metastases	in	men	75	years	old	or	older	reached	a	nadir	in2011	compared	to	2004	(ir	0	81		95%	ci	0	74-0	90		p	<0	01)	and	it	increased	in2012	compared	to	2011	(ir	1	13		95%	ci	1	02-1	24		p	<0	05)		the	risk	of	cancerspecific	mortality	significantly	increased	in	men	diagnosed	with	pelvic	lymphnode	metastases	(hr	4	5		95%	ci	4	2-4	9		p	<0	01)	and	distant	metastases	(hr21	9		95%	ci	21	2-22	7		p	<0	01)	compared	to	men	with	nonmetastatic	disease	conclusions		the	incidence	of	pelvic	lymph	node	metastases	is	increasingcoincident	with	a	decline	in	the	detection	of	localized	disease		whether	thisportends	an	increase	in	the	burden	of	advanced	disease	or	simply	reflectsdecreased	lead	time	remains	unclear		however		this	should	be	monitored	closely	asthe	increase	in	n1	disease	reflects	an	increase	in	incurable	prostate	cancer	atdiagnosis	
